Xinxiang Tuoxin Pharmaceutical Co. LtdOctober 18, 2021

FDA 483 - Xinxiang Tuoxin Pharmaceutical Co. Ltd - October 18, 2021

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Xinxiang Tuoxin Pharmaceutical Co. Ltd

Record Details

Xinxiang Tuoxin Pharmaceutical Co., Ltd., a drug intermediates manufacturer in Xinxiang, China, was cited for significant quality control deficiencies during an FDA inspection. Observations included poorly maintained manufacturing equipment with potential for product contamination, unvalidated laboratory analytical methods, and inadequate investigation of deviations. Furthermore, the firm lacked proper electronic controls for data integrity in computerized systems.

Company: Xinxiang Tuoxin Pharmaceutical Co. Ltd
Inspection Date: October 18, 2021
Product Type: Drugs
Office: Office of Biological Products Operations - Division I
Person: Marcus A. Ray (Supervisory Consumer Safety Officer, China Office)

Open in Dashboard

ID · e3cddd0f-9c6a-43cd-b158-071155413a75